NCT05371899View on ClinicalTrials.gov

Mass Balance Study of [14C]Chiauranib

NACompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 20, 2022

Primary Completion Date

March 18, 2024

Study Completion Date

March 18, 2024

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Chiauranib

Take Chiauranib 50mg orally once daily

Trial Locations (1)

21500

The First Affiliated Hospital of Suzhou University, Suzhou

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY

NCT05371899 - Mass Balance Study of [14C]Chiauranib | Biotech Hunter | Biotech Hunter